


# Model using routine clinical data may predict pancreatic cancer risk

February 14 2022

---



(HealthDay)—A model using routine clinical information can predict

pancreatic ductal adenocarcinoma (PDA) following diagnosis of impaired fasting glucose (IFG), according to a study published in the January issue of the *European Journal of Gastroenterology & Hepatology*.

Ben Boursi, M.D., from the University of Pennsylvania in Philadelphia, and colleagues developed and internally validated a new model to predict PDA risk among those newly diagnosed with IFG. The analysis included 138,232 eligible patients with an initial IFG diagnosis (1995 to 2013).

The researchers found that during the study period, 0.2% of individuals were diagnosed with PDA within three years, with a median time from IFG diagnosis to clinical PDA diagnosis of 326 days. Age, body mass index, proton pump inhibitor use, total cholesterol, [low-density lipoprotein cholesterol](#), [alanine aminotransferase](#), and alkaline phosphatase were included in the final prediction model. The model showed good discrimination and calibration.

"Over the last few years our team has been aiming to build a model whereby people at risk of developing [pancreatic cancer](#) could be flagged at as early a stage as possible allowing curative resection of the disease," Boursi said. "If our models are validated in a prospective study, this finding could extend our ability to detect pancreatic ductal adenocarcinomas at an earlier stage and improve health outcomes."

**More information:** Ben Boursi et al, A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes, *European Journal of Gastroenterology & Hepatology* (2021). [DOI: 10.1097/MEG.0000000000002052](https://doi.org/10.1097/MEG.0000000000002052)

Copyright © 2021 [HealthDay](#). All rights reserved.

Citation: Model using routine clinical data may predict pancreatic cancer risk (2022, February 14) retrieved 8 May 2024 from <https://medicalxpress.com/news/2022-02-routine-clinical-pancreatic-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.